CME (CME Group Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by CME officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-29 | Deborah J Lucas | Director | A | — | — |
| 2026-06-29 | Dennis Suskind | Director | A | — | — |
| 2026-06-29 | MARTIN J GEPSMAN | Director | A | — | — |
| 2026-06-29 | Kathryn Benesh | Director | A | — | — |
| 2026-06-29 | Daniel G Kaye | Director | A | — | — |
| 2026-06-29 | Rahael Seifu | Director | A | — | — |
| 2026-06-29 | Robert J JR Tierney | Director | A | — | — |
| 2026-06-29 | Patrick J Mulchrone | Director | A | — | — |
| 2026-06-29 | Timothy S. Bitsberger | Director | A | — | — |
| 2026-06-29 | Bryan T Durkin | Director | A | — | — |
| 2026-06-29 | Harold Eugene Jr. Ford | Director | A | — | — |
| 2026-06-29 | Patrick W Maloney | Director | A | — | — |
| 2026-06-29 | Charles P Carey | Director | A | — | — |
| 2026-06-29 | Elizabeth A Cook | Director | A | — | — |
| 2026-06-29 | William W Hobert | Director | MIXED | — | — |
| 2026-06-29 | HOWARD J SIEGEL | Director | A | — | — |
| 2026-06-29 | Phyllis M Lockett | Director | A | — | — |
| 2026-06-29 | WILLIAM R SHEPARD | Director | MIXED | — | — |
| 2026-05-19 | Hilda Harris Piell | Sr MD & Chief HR Officer | Sell | — | — |
| 2026-05-18 | TERRENCE A DUFFY | Chairman and CEO | Sell | — | — |
| 2026-03-30 | WILLIAM R SHEPARD | Director | Buy | — | — |
| 2026-03-23 | Jonathan L Marcus | Sr MD General Counsel | Sell | — | — |
| 2026-03-19 | Jonathan L Marcus | Sr MD General Counsel | Sell | — | — |
| 2026-03-17 | Sunil Cutinho | Chief Information Officer | MIXED | — | — |
| 2026-03-17 | Jack J Tobin | MD Chief Accounting Officer | MIXED | — | — |
| 2026-03-17 | Lynne Fitzpatrick | President and CFO | MIXED | — | — |
| 2026-03-17 | Derek Sammann | Sr MD Gl Hd Commodities Mkts | MIXED | — | — |
| 2026-03-17 | Julie Winkler | Sr MD Chief Commercial Officer | MIXED | — | — |
| 2026-03-17 | Ken Vroman | Chief Transformation Officer | MIXED | — | — |
| 2026-03-17 | TERRENCE A DUFFY | Chairman and CEO | MIXED | — | — |
| 2026-03-17 | Suzanne Sprague | COO & Global Head of Clearing | MIXED | — | — |
| 2026-03-17 | Hilda Harris Piell | Sr MD & Chief HR Officer | MIXED | — | — |
| 2026-03-17 | Jonathan L Marcus | Sr MD General Counsel | MIXED | — | — |
| 2026-03-17 | Timothy Francis McCourt | Sr MD Global Head Equity & FX | MIXED | — | — |
| 2026-03-12 | Ken Vroman | Chief Transformation Officer | Sell | — | — |
| 2026-03-12 | Jack J Tobin | MD Chief Accounting Officer | G | — | — |
| 2026-03-09 | Elizabeth A Cook | Director | Sell | — | — |
| 2026-02-23 | Bryan T Durkin | Director | Sell | — | — |
| 2026-02-20 | MARTIN J GEPSMAN | Director | Sell | — | — |
| 2026-02-09 | Dennis Suskind | Director | Sell | — | — |
| 2026-01-02 | TERRENCE A DUFFY | Chairman and CEO | F | — | — |
| 2026-01-02 | WILLIAM R SHEPARD | Director | Buy | — | — |
| 2025-12-15 | TERRENCE A DUFFY | Chairman and CEO | Sell | — | — |
| 2025-11-21 | Derek Sammann | Sr MD Gl Hd Commodities Mkts | MIXED | — | — |
| 2025-11-12 | Hilda Harris Piell | Sr MD & Chief HR Officer | G | — | — |
| 2025-11-04 | Harold Eugene Jr. Ford | Director | Sell | — | — |
| 2025-09-26 | WILLIAM R SHEPARD | Director | Buy | — | — |
| 2025-09-18 | Jonathan L Marcus | Sr MD General Counsel | Sell | — | — |
| 2025-09-17 | Hilda Harris Piell | Sr MD & Chief HR Officer | MIXED | — | — |
| 2025-09-17 | TERRENCE A DUFFY | Chairman and CEO | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | CEO | 382,910 | — |
| — | Director | 264,063 | — |
| — | Director | 219,738 | — |
| — | Director | 149,218 | — |
| — | Director | 135,743 | — |
| — | Director | 127,263 | — |
| — | Former Sr MD&Pres.Clr&PostTrad | 120,590 | — |
| — | CEO | 116,222 | — |
| — | Director | 107,338 | — |
| — | Director | 104,767 | — |
| — | Director | 75,859 | — |
| — | Sr MD Chief Information Office | 74,564 | — |
| — | Director | 73,947 | — |
| — | Director | 70,309 | — |
| — | Chairman and CEO | 64,634 | — |
| — | Sr MD Chief Financial Officer | 55,238 | — |
| — | Director | 54,130 | — |
| — | CFO & Sr MD Finance & Corp Dev | 48,353 | — |
| — | Director | 43,652 | — |
| — | Director | 42,004 | — |
| — | Sr MD Gen Counsel & Corp Secr | 41,746 | — |
| — | MD Products & Services | 40,570 | — |
| — | Director | 39,651 | — |
| — | Sr MD Chief Operating Officer | 36,833 | — |
| — | Sr MD Equity Index Prod & Svcs | 31,772 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the CME quote page; the site-wide leaderboard is on the insider transactions hub.